Evidence map›Paper›PMID 39335451›Full record

ReviewBiomedicines2024

Animal Models of Retinopathy of Prematurity: Advances and Metabolic Regulators.

Meenakshi Maurya, Chi-Hsiu Liu, Kiran Bora, Neetu Kushwah, Madeline C Pavlovich, Zhongxiao Wang, Jing Chen

Abstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Biglycan stimulates retinal pathological angiogenesis via up-regulation of CXCL12 expression in pericytes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meenakshi MauryaDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.ORCID 0000-0002-2632-4789
Chi-Hsiu LiuDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
Kiran BoraDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.ORCID 0000-0002-6105-5211
Neetu KushwahDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.ORCID 0000-0003-4032-8484
Madeline C PavlovichDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
Zhongxiao WangDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
Jing ChenDepartment of Ophthalmology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.ORCID 0000-0002-9183-8698

Funding

RORalpha mediates chronic subretinal inflammation associated with AMDR01EY024963 · NEI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, JING · 2015 to 2025
$4.2M
Regulation of RPE degeneration by REV-ERBalphaR01EY031765 · NEI · BOSTON CHILDREN'S HOSPITAL · PI JING CHEN · 2020 to 2026
$2.7M
Wnt signaling-mediated control of blood-retinal barrierR01EY028100 · NEI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, JING · 2017 to 2021
$2.2M
NEI NIH HHS EY024963, EY028100, and EY031765NEI NIH HHS R01 EY024963NEI NIH HHS R01 EY028100NEI NIH HHS R01 EY031765
6 · The paper itself

Abstract

Retinopathy of prematurity (ROP) is a primary cause of visual impairment and blindness in premature newborns, characterized by vascular abnormalities in the developing retina, with microvascular alteration, neovascularization, and in the most severe cases retinal detachment. To elucidate the pathophysiology and develop therapeutics for ROP, several pre-clinical experimental models of ROP were developed in different species. Among them, the oxygen-induced retinopathy (OIR) mouse model has gained the most popularity and critically contributed to our current understanding of pathological retinal angiogenesis and the discovery of potential anti-angiogenic therapies. A deeper comprehension of molecular regulators of OIR such as hypoxia-inducible growth factors including vascular endothelial growth factors as primary perpetrators and other new metabolic modulators such as lipids and amino acids influencing pathological retinal angiogenesis is also emerging, indicating possible targets for treatment strategies. This review delves into the historical progressions that gave rise to the modern OIR models with a focus on the mouse model. It also reviews the fundamental principles of OIR, recent advances in its automated assessment, and a selected summary of metabolic investigation enabled by OIR models including amino acid transport and metabolism.

Indexed as

amino acidanimal modelshypoxiametabolismoxygen-induced retinopathyretinopathy of prematurity

Identifiers

PMID39335451
PMCPMC11428941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.